We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
-15.27%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$72.6M
AUM Growth
+$36.2M
Cap. Flow
+$39.4M
Cap. Flow %
54.35%
Top 10 Hldgs %
38.26%
Holding
170
New
94
Increased
8
Reduced
36
Closed
17

Sector Composition

Rank Sector Weight
1 Energy 48.57%
2 Healthcare 38.33%
3 Utilities 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CLVS
126
DELISTED
Clovis Oncology, Inc.
CLVS
$144K 0.2%
7,526
-473
-6% -$10K
RXDX
127
DELISTED
Ignyta, Inc.
RXDX
$144K 0.2%
21,317
-1,321
-6% -$10.9K
CEMP
128
DELISTED
Cempra, Inc.
CEMP
$141K 0.19%
+8,058
New +$146K
BLCM
129
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$133K 0.18%
1,420
-89
-6% -$9.69K
SRPT icon
130
Sarepta Therapeutics
SRPT
$1.66B
$132K 0.18%
6,770
-433
-6% -$7.57K
LUMO
131
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$128K 0.18%
781
-51
-6% -$10.3K
RDUS
132
DELISTED
Radius Health, Inc.
RDUS
$128K 0.18%
4,086
-259
-6% -$8.96K
RLYP
133
DELISTED
RELYPSA INC COM
RLYP
$125K 0.17%
9,227
-575
-6% -$9.78K
OMED
134
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$125K 0.17%
+12,369
New +$145K
TTPH
135
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$123K 0.17%
+1,324
New +$132K
SRRA
136
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$121K 0.17%
+448
New +$143K
IBRX icon
137
ImmunityBio
IBRX
$7.44B
$120K 0.17%
+14,563
New +$137K
GBT
138
DELISTED
Global Blood Therapeutics, Inc.
GBT
$120K 0.17%
+7,582
New +$135K
SGYP
139
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$120K 0.17%
43,341
-2,702
-6% -$9.79K
VTAE
140
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$116K 0.16%
+17,530
New +$159K
NWBO
141
DELISTED
Northwest Biotherapeutics, Inc. Common stock
NWBO
$115K 0.16%
+78,696
New +$155K
PTLA
142
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$107K 0.15%
5,232
-329
-6% -$10.4K
KDNY
143
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$102K 0.14%
+1,593
New +$129K
TVRD
144
Tvardi Therapeutics
TVRD
$23.5M
$101K 0.14%
452
-29
-6% -$8.66K
ARDX icon
145
Ardelyx
ARDX
$1.24B
$100K 0.14%
12,922
-795
-6% -$7.83K
PBYI icon
146
Puma Biotechnology
PBYI
$406M
$98K 0.14%
+3,321
New +$150K
BCRX icon
147
BioCryst Pharmaceuticals
BCRX
$2.37B
$74K 0.1%
+26,246
New +$116K
SEP
148
DELISTED
Spectra Engy Parters Lp
SEP
$70K 0.1%
+1,449
New +$65.8K
CLDX icon
149
Celldex Therapeutics
CLDX
$2.77B
$65K 0.09%
+1,150
New +$129K
NS
150
DELISTED
NuStar Energy L.P.
NS
$64K 0.09%
+1,588
New +$55.3K

Similar funds

Virtus ETF Advisers's Q1 2016 Portfolio in Review

As of Q1 2016, Virtus ETF Advisers held 170 positions worth $72.6M, up 99% from $36.4M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Virtus ETF Advisers deployed $39.4M of net new capital in Q1 2016, opening 94 new positions and adding to 8 existing holdings. Its largest new stake was Energy Transfer Partners L.p.: 127,467 shares worth $4.12M.

By sector, the portfolio is most concentrated in Energy at 49% of assets, up from 27% a quarter earlier, followed by Healthcare and Utilities.

On the sell side, the largest reduction was Spectra Energy Corp Wi, an estimated $258K trimmed.

  • Virtus ETF Advisers's largest Q1 2016 buy was Energy Transfer Partners L.p.: 127,467 shares worth $4.12M.
  • Virtus ETF Advisers added most to Buckeye Partners, L.P. in Q1 2016, an estimated $1.73M increase.
  • Virtus ETF Advisers's biggest Q1 2016 reduction was Spectra Energy Corp Wi, cutting an estimated $258K.
  • Virtus ETF Advisers fully exited Aegerion Pharmaceuticals in Q1 2016, selling an estimated $656K.
  • Virtus ETF Advisers's ten largest holdings make up 38% of its $72.6M portfolio in Q1 2016.
  • Virtus ETF Advisers opened 94 new positions and closed 17 in Q1 2016.
  • Virtus ETF Advisers's portfolio value rose 99% quarter-over-quarter to $72.6M.

Based on Virtus ETF Advisers's 13F filing for Q1 2016, filed 16 May 2016.